SciSparc Ltd.
corporate_fare Company Profile
SciSparc Ltd. (NASDAQ:SPRC) is a publicly traded company in the Life Sciences sector. Wiseek monitors SPRC SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- SciSparc's NeuroThera Launches Phase IIb Trial for Tourette Syndrome Drug
- 10% Shareholder Files Intent to Sell $583K in SciSparc Stock
- NeuroThera Labs, SciSparc Subsidiary, Closes CliniQuantum Acquisition Valued at $9.46M
- SciSparc Subsidiary NeuroThera Labs Receives Conditional TSX Approval for CliniQuantum Acquisition, Amends Terms
- SciSparc Subsidiary Nears Major Acquisition Close with Conditional Regulatory Approval
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for SPRC, detected from its recent SEC filings · based on capital-structure filings through 2026-02-17.
Massive Share Registration for Resale · Enables Significant Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
SPRC files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.